Beta Bionics reported second quarter 2026 financial results with net sales of $32.0 million, a 38% increase from the prior year period. Gross margin expanded to 59.0%, up 524 basis points year-over-year. The company incurred a net loss of $23.4 million and an adjusted EBITDA loss of $17.7 million. Beta Bionics updated its full year 2026 revenue guidance to approximately $131 million to $136 million, unchanged from previous estimates, while raising the estimated gross margin range to 58.5%–59.5%. The company initiated enrollment for a pivotal trial of its iLet device in adults with type 2 diabetes and updated expectations to fully commercialize its Mint patch pump by the end of the second quarter of 2027. Beta Bionics operates in the medical device industry, designing and commercializing automated insulin delivery systems for people with diabetes.